• About
  • Subscribe
  • Advertise
  • Contact
Friday, July 17, 2026
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Local

Experience InMode’s Envision dry eye platform at upcoming events

by Myles Hume
September 5, 2023
in Conferences, Events, Local, News
Reading Time: 3 mins read
A A
queensland inmode dry eye treatment envision

Envision is said to be a viable therapeutic option for patients with moderate to severe dry eye disease.

Share on FacebookShare on Twitter

InMode, which recently made its non-surgical Envision dry eye platform available to Australian eyecare professionals, will be exhibiting at two upcoming conferences, as well as hosting North American optometrist Dr Bruce Dornn for an Australian roadshow where he will discuss his experience the technology. 

The company will be showcasing Envision at:

O=MEGA 23/4th World Congress of Optometry
8-10 September, Melbourne Convention and Exhibition Centre
InMode will be exhibiting and demonstrating the InMode Envision platform at the trade fair.
Stand number: A1
https://www.omega-event.org/

RANZCO Congress 2023
20-23 October, Perth Convention and Exhibition Centre
InMode will be exhibiting and demonstrating the InMode Envision platform in the trade fair.
Stand number: 27

Dr Bruce Dornn Australia tour
InMode will also be welcoming Dr Bruce Dornn to Australia. He’s a Canadian optometrist and early adopter of the Envision platform for dry eye four years ago.

Dr Bruce Dornn.

He will be presenting at:

  • QT Hotel Sydney, 16 October
  • QT Hotel Melbourne, 17 October

“Envision has been a game changer for my practice as I can effectively treat the cause of dry eye disease with life-changing results, plus with Morpheus8 I can build an additional income stream by tightening the skin in the periorbital area and full face,” Dornn said.

Read more about Dornn’s experience with the Envision platform in this May 2023 interview with Insight.

CPD approval pending

For more information, RSVP, or to book a demonstration at any of the above events, contact:
Evan Crealy
Business Development Manager – Envision, InMode ANZ
0491 221 168 | evan.crealy@inmodemd.com

The InMode Envision platform is described as a non-surgical, non-drug alternative for dry eye.

Envision from InMode is a revolutionary eyecare platform featuring three technologies.

The Forma-I handpiece is the primary treatment on the platform and features bipolar RF to address the symptoms of dry eye disease caused by meibomian gland dysfunction (MGD) using controlled dermal heating to aid gland expression.

Envision’s secondary treatment is Lumecca-I, which InMode said delivers precise, targeted, intense pulsed light (IPL) procedures to treat inflammatory conditions associated with dry eye disease.

The third – and complementary – treatment is MORPHEUS8. It adopts fractional RF microneedling for complete face and body dermal resurfacing, tightening and subdermal remodelling.

More information can be found here.

More reading

InMode brings new dry eye care approach to Australia

Positive findings for InMode Envision platform in dry eye study

Related Posts

Optos colour ultra-widefield fundus photograph (left) and autofluorescence (right) with the posterior edge of a ciliary body melanoma visible in the inferonasal periphery. Image: Dr Lindsay McGrath.

Confidence in the capture with Optos

by Rob Mitchell
July 16, 2026

A Brisbane ophthalmologist finds there’s one diagnostic tool giving her confidence that goes beyond the clinic and the outcomes for...

Dr Cathleen McCabe gave a presentation on AI and robotics in eye surgery.

AUSCRS: AI and robotics are already reshaping cataract surgery

by Rob Mitchell
July 16, 2026

Artificial intelligence and robotics in ophthalmology are no longer concepts on the horizon – they are already changing the way...

Abbie Hopkinson. Images: Specsavers.

Specsavers Stories: Abbie Hopkinson

by staff writer
July 16, 2026

Specsavers’ Dame Mary Perkins Award for Outstanding Patient Care honours optometrists who have made an extraordinary impact on the vision...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2026 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Products
    • Ophthalmic Treatments
      • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2026 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited